Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

CytomX Therapeutics Announces Closing of Public Offering of Common Stock

Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson's Disease and Provides Clinical Update

Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases

CytomX Therapeutics Announces Pricing of Public Offering of Common Stock